Role of microRNAs (miRNAs) in tumor angiogenesis

Abstract

Angiogenesis is a controlled process that occurs in; developmental events of embryonic and post embryonic periods, wound and tissue healing and also events of female reproductive system. Nevertheless angiogenesis can be observed as an uncontrolled and so a pathological process in cancers, some inflamtory diseases and eye diseases. miRNAs are non protein coding small RNA molecules. The researches shoved that miRNAs play some important roles in the cell. Also the expression changes of some miRNAs is associated with angiogenesis and cancer development. For these reasons in recent years, the interest on miRNAs has increased in the studies aiming to understand molecular basis of cancer and treatment of it. Key words: Cancer, angiogenesis, miRNA

Keywords

• Cancer, angiogenesis,miRNA

Tümör anjiyogenezinde mikroRNA (miRNA)'ların rolü

Abstract

Anjiyogenez; embriyonik-post-embriyonik dönemde gelişme, yara ve doku hasarlarının iyileştirilmesi ve dişi üreme sistemindeki olaylarda, kontrol altında gerçekleşmekte olan bir süreçtir. Kanserler, bazı inflamatuvar durumlar ve göz hastalıklarında kontrolsüz gerçekleşip patolojik bir durum olarak gözlenmektedir. miRNA'lar protein kodlamayan küçük RNA molekülleridir. Yapılan araştırmalar, miRNA'ların hücrede önemli roller üstlendiğini göstermiştir. Ayrıca bazı miRNA'ların ekspresyonlarının değişimi, kanser gelişimiyle ve anjiyogenezle ilişkilendirilmiştir. Bu nedenle son yıllarda ilgi kanserin moleküler temelinin anlaşılması ve tedavisine yönelik çalışmalarda miRNA'lara olan ilgi artmıştır. Anahtar kelimeler: Kanser, anjiyogenez, miRNA

Keywords

• Kanser, anjiyogenez, miRNA

References

1. Tekeli SÖ, Emerk K. Endotel progenitör hücreleri. Marmara Medical Journal 2007; 20(1): 59-65.
2. Olgar Ş, Yetgin S. Anjiogenezis. Çocuk Sağlığı ve Hastalıkları Dergisi 2003;(46): 139-147.
3. Turgut B, Mete Güler M, Demir T, Türkçüoğlu P, Çeliker Ü. Oküler anjiyogenezde vasküler endotelyal büyüme faktörünün rolü. Türkiye Klinikleri Oftalmoloji Dergisi 2007; 16(1): 38-46.
4. Tepper OM, Sealove BA, Murayama T, Asahara T.Newly. Emerging concepts in blood vessel growth: recent discovery of endothelial progenitor cells and their function in tissue regeneration. Journal of Investigative Medicine 2003; 51(6): 353-359.
5. Kılıç D, Yıldırım Ö, Şahin S, Pamir MN. Glial tümörlerin anjiyogenezi. Türk Nöroşirürji Dergisi 2005; 15(1): 1-9.
6. Folkman J, Shing Y. Angiogenesis. The Journal of Biological Chemistry 1992; 267(16): 10931-10934.
7. Menakuru SR, Brown NJ, Staton CA, Reed MW. Angiogenesis in pre-malignant conditions. British Journal of Cancer 2008; 99(12): 1961-1966.
8. Gupta, M. K. and Qin, R. Y. Mechanism and its regulation of tumor-induced angiogenesis. World Journal of Gastroenterology 2003; (9): 1144-1155.

9. Liekens, S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochemical Pharmacology 2001;(61): 253-270.
10. Özuysal S. Tümoral anjiogenezis. Türk Patoloji Dergisi 2001; 17(3-4): 90-93.
11. Konukoğlu D. Turhan MS. Anjiyogenezin temel moleküler mekanizmaları ve tümör anjiyogenezi. Cerrahpaşa Tıp Dergisi 2004; 36(1): 42-48.
12. Zhang T, Niu X, Liao L, Cho EA, Yang H. The contributions of hıf-target genes to tumor growth in RCC. PLoS One 2013; 8(11): e80544.
13. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nature Reviews Clinical Oncology 2009; 6(10): 587-595.
14. Cheng Q, Yi B, Wang A, Jiang X. Exploring and exploiting the fundamental role of microRNAs in tumor pathogenesis. Journal of OncoTargets and Therapy 2013;(6): 1675-1684.
15. Vimalraj S, Miranda PJ, Ramyakrishna B, Selvamurugan N. Regulation of breast cancer and bone metastasis by microRNAs. Disease Markers 2013; 35(5): 369-387.
16. Kwak PB, Iwasaki S, Tomari Y. The microRNA pathway and cancer. Cancer Science 2010; (101): 2309-2315.
17. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences of the USA 2004;(101): 2999–3004.
18. Le Quesne J, Caldas C. Micro-RNAs and breast cancer. Moleculer Oncology 2010;(4): 230-241.
19. Saydam F, Değirmenci İ, Güneş HV. MikroRNA’lar ve kanser. Dicle Tıp Dergisi 2011; 38 (1): 113-120.
20. Tsai YH, Wu MF, Wu YH, Chang SJ, Lin SF, Sharp TV, et al. The M type K15 protein of Kaposi’s sarcoma associated herpesvirus regulates microRNA expression via its SH2- binding motif to induce cell migration and invasion. Journal of Virology 2009;(83): 622–632.
21. Loffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermüller J, Kretzschmar AK, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007;(110): 1330–1333.
22. Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K, et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood 2006;(108): 3068–3071.
23. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008;(132): 875–886.
24. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;(435): 828–833.
25. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Research 2005;(65): 9628–9632.
26. Cimmino A, Calin GA, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the USA 2005;(102): 13944–13949.
27. Aqeilan R, Calin G, Croce C. miR-15a and miR-16-1 in cancer: discovery function and future perspectives. Cell Death and Differentiation 2010; 17(2): 215-220.
28. Bruchova H, Yoon D, Agarwal AM, Mendell J, Prchal JT. Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Experimental Hematology 2007;(35): 1657–1667.
29. Lee DY, Deng Z, Wang CH, Yang BB. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proceedings of the National Academy of Sciences of the USA 2007;(104): 20350–20355.
30. Pola R, Ling LE, Silver M, Corbley MJ, Kearney M, Blake Pepinsky R, et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nature Medicine 2001;(7): 706– 711.
31. Wurdinger T, Tannous BA, Saydam O, Skog J, Grau S, Soutschek J, et al. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell 2008;(14): 382–393.
32. Krützfeldt J, Rajewsky N, Braich R, Rajeev K, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005; 438(7068): 685-689.
33. Hua Z, Lv Q, Ye W, Wong CK, Cai G, Gu D, et al. miRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS ONE 2006; 1: e116.
34. Campagnolo L, Leahy A, Chitnis S, Koschnick S, Fitch MJ, Fallon JT, et al. EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury. American Journal of Patholy 2005;(167): 275–284.
35. De Maziere A, Parker L, Van Dijk S, Ye W, Klumperman J. Egfl7 knockdown causes defects in the extension and junctional arrangements of endothelial cells during zebrafish vasculogenesis. Developmental Dynamics 2008;(237): 580– 591.
36. Wang S, Olson EN. AngiomiRs-Key Regulators of Angiogenesis. Current Opinion in Genetics & Development 2009; 19(3): 205–211.
37. Gumbiner BM. Regulation of cadherin-mediated adhesion in morphogenesis. Nature Reviews Molecular Cell Biology 2005;(6):622–634.
38. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nature Cell Biology 2010; 12(3): 247-256.